Aclarion, Inc. (ACON) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Aclarion, Inc. is a healthcare technology company leveraging magnetic resonance spectroscopy (MRS) to optimize clinical treatments via its Nociscan reports. The company is classified as an emerging growth company and a smaller reporting company. As of November 10, 2025, there were 671,371 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $18,942 | $14,407 | $57,251 | $35,492 |
| Gross Profit | $4,386 | $(6,925) | $5,037 | $(28,610) |
| Net Loss | $(1,706,294) | $(1,366,176) | $(5,344,487) | $(5,003,355) |
| Cash & Equivalents | $11,341,336 | $453,661 | $11,341,336 | $453,661 |
| Total Liabilities | $699,747 | $1,153,426 | $699,747 | $1,153,426 |
| Stockholders' Equity | $12,500,551 | $970,057 | $12,500,551 | $970,057 |
Liquidity: Cash and cash equivalents increased significantly to approximately $11.3 million as of September 30, 2025, compared to $453,661 at year-end 2024. Management believes current cash will fund operations through the first quarter of 2027.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 31.5% in Q3 2025 and 61.3% for the nine months ended September 30, 2025, driven by growing volumes of Nociscan reports in the UK market following local coverage decisions.
- Operating Expenses: Total operating expenses rose 42.4% in Q3 2025 ($1.84M vs $1.29M) and 37.7% for the nine-month period. Increases were primarily due to:
- Sales & Marketing: Higher post-market clinical expenses (initiation of the Clarity trial) and product marketing consulting.
- R&D: Increased patent maintenance fees and regulatory consulting.
- G&A: Accruals for incentive-based performance bonuses and higher D&O insurance costs.
- Debt Elimination: The company had no interest expense or debt-related losses in 2025, compared to significant interest and debt extinguishment charges in 2024, as all unsecured non-convertible notes were retired.
- Settlement Costs: The company recorded $672,500 in penalties and settlements in the nine months ended September 30, 2025, related to a dispute under an investment banking agreement ("fee tail" provision).
Guidance, Outlook, and Risks
- Capital Raising: The company raised approximately $20.1 million in gross proceeds during the first nine months of 2025 through public offerings and registered direct offerings. A subsequent registered direct offering in October 2025 raised an additional ~$2.5 million.
- Outlook: Management expects revenue growth to continue as more insurance payors are onboarded and scan volumes increase. R&D expenses are expected to rise as enrollment in the CLARITY Trial expands.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to material weaknesses related to limited segregation of duties and a lack of adequate accounting resources for complex transactions. Remediation efforts are ongoing with an outside firm.
- Risks: The company faces risks typical of early-stage development, including dependence on key personnel, limited operating history, and the need for additional funding to continue technology development and commercialization.
Investor Verification Checklist
- Cash Runway: Verify the sustainability of the $11.3M cash position against the projected burn rate through Q1 2027.
- Revenue Quality: Assess the concentration of revenue in the UK market and the timeline for reimbursement approvals in other jurisdictions.
- Internal Control Remediation: Monitor progress on fixing material weaknesses in internal controls over financial reporting.
- Dilution: Review the impact of recent and potential future equity offerings (including warrant exercises) on shareholder dilution.
- Clarity Trial: Track the enrollment and results of the Clarity trial, which is a primary driver of current marketing and R&D spend.